The domestic new drug 'Ja Q Bo' is entering the Chinese market, the largest market for gastroesophageal reflux disease.
JEIL PHARMACEUTICAL's new drug development subsidiary Onconic Therapeutics noted on the 18th that its partner, Livzon Pharmaceutical, has completed Phase 3 clinical trials for its gastroesophageal reflux disease new drug 'Zastaprazan' (domestic product name: Ja Q Bo) and submitted a product license application to the National Medical Products Administration (NMPA) of China.
Onconic Therapeutics entered into a technology transfer agreement granting exclusive rights in the Chinese market with Livzon, the leading corporation in gastrointestinal treatments in China, in April 2023. Livzon received approval for its Phase 3 clinical trial plan (IND) in November 2023 and completed the clinical trials within seven months. Through this license application, it will enter the P-CAB (potassium competitive acid blocker) market in China.
Ja Q Bo is a new drug for gastroesophageal reflux disease in the P-CAB category that was initially researched by JEIL PHARMACEUTICAL and further developed by Onconic Therapeutics.
According to global market research firm IQVIA, the global gastroesophageal reflux disease market is expected to grow to 40 trillion won this year, with the Chinese market evaluated at 4 trillion to 6 trillion won.
The current size of the Chinese P-CAB market is 241.4 billion won, with an annual growth rate of 81.22% last year.
A representative from Onconic Therapeutics said, "Livzon, which has strong sales capabilities and performance in the Chinese gastrointestinal therapeutic market, is expected to rapidly transition the existing PPI market to the P-CAB market" and added, "The early completion of clinical trials and an expedited approval schedule will accelerate the realization of revenue in the Chinese market."